The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β‐Catenin Signaling Pathway
The FASEB Journal · 2025
DOI: 10.1096/fj.202501681r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Shuo Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Wnt Signaling Pathway, Radiation Tolerance, Esophageal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation, Hebei Province Science and Technology Support Program, Chengde Municipal Science and Technology Bureau.
Abstract (Originalsprache)
Actin‐like protein 6A (ACTL6A) is thought to be associated with the survival and prognosis of patients with a variety of human cancers. This study investigates the effect of ACTL6A knockdown on ESCC radiosensitivity and explores molecular mechanisms that may enhance radiotherapy efficacy. The ACTL6A expression level was increased in esophageal squamous carcinoma cells after radiation irradiation. The protein expression level of ACTL6A in tumor tissue samples of clinical esophageal squamous cell carcinoma patients was analyzed by immunohistochemistry, and it was found that the prognosis of the high expression group was worse than that of the low expression group. Further knocking down the ACTL6A gene in esophageal squamous cell carcinoma cells, it was found that ACTL6A could regulate the proliferation, migration, invasion, DNA damage repair, cell cycle, and apoptosis of esophageal squamous cell carcinoma cells, which further affected the radiosensitivity of esophageal squamous cell carcinoma cells. Through functional enrichment analysis of gene set enrichment and validation of the mechanism using the Wnt pathway inhibitor XAV939, it was shown that ACTL6A is involved in the regulation of the Wnt/β‐catenin signaling pathway. Knockdown of ACTL6A can inhibit the activity of this pathway, thereby increasing the radiosensitivity of esophageal squamous cell carcinoma. ACTL6A may become an important therapeutic target for esophageal squamous cell carcinoma, providing a necessary theoretical basis for future treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Radiation Oncology, Chengde Central Hospital, Chengde, Hebei, China.
- Department of Radiation Oncology, Weifang People's Hospital, Weifang, Shandong, China.
- Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
ORCID-Profile: Shuo Zhou
Förderung
- Natural Science Foundation
- Hebei Province Science and Technology Support Program
- Chengde Municipal Science and Technology Bureau
- Natural Science Foundation of Hebei Province
Zitieren
APA
Zhou, S., Sun, T., Liu, L., Guo, D., Zhang, X., Shen, W., Gao, S., & Zhu, S. (2025). The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β‐Catenin Signaling Pathway. The FASEB Journal. https://doi.org/10.1096/fj.202501681r
Vancouver
Zhou S, Sun T, Liu L, Guo D, Zhang X, Shen W, et al. The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β‐Catenin Signaling Pathway. The FASEB Journal. 2025. doi:10.1096/fj.202501681r
BibTeX
@article{Zhou2025,
author = {Zhou, Shuo and Sun, Tongyou and Liu, Likun and Guo, Dong and Zhang, Xueyuan and Shen, Wenbin and Gao, Shaolin and Zhu, Shuchai},
title = {The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β‐Catenin Signaling Pathway},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202501681r}
}
EUVIMED